Role of Interleukin-28B in clearance of HCV in acute and chronic hepatitis patients in Kirkuk city
https://doi.org/10.24017/science.2018.2.24
Abstract views: 1044 / PDF downloads: 803Abstract
A cross sectional study was conducted in Kirkuk city from June 2017 to March 2018. The number of hepatitis patient understudy were 62 hepatitis C (27 acute and 35 chronic) whose ages were between 20-75 years old. The purpose of this study was to evaluate the effect of IL28B in the clearance of HCV. These patients admitted to Hepatology and Gastroenterology centers of Kirkuk. The control group who were matched to the patients studied, included 30 individuals who admitted to blood bank for blood donation, for molecular test of HCV Real-time quantitative test and serum IL-28B ELISA. The study exhibited that 81.48 % of acute HCV patient who positive by ELISA were positive by PCR and 82.86 % of chronic HCV patients were positive by PCR with highly significant relation between them. Regarding the relation of IL-28B with HCV infection, the study presented that the highest mean of IL-28B was recorded among PCR –ve acute HCV patients (17.78 pg/ml) followed by PCR +ve acute HCV and the lowest means was found in the control group with highly significant differences among the groups. The study indicated that the highest mean of IL-28B was recorded among PCR –ve chronic HCV patients (17.78 pg/ml) followed by PCR +ve chronic HCV and the lowest means was found in the control group with highly significant relation. The study showed that the highest mean of ALT and AST were found in acute HCV patients (72.06 and 36.73 IU/ml) respectively followed by chronic HCV and the control group with highly significant relation among the groups.
Keywords:
HCV, viral load, IL-28B, Kirkuk
References
[1] A. ASLD/IDSA HCV Guidance Panel, R.T Chung, G.L Davis,DM Jensen, et al, "Hepatitis C guidance: AASLD?IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus", Hepatology, 62(3), pp. 932-954, 2015.
https://doi.org/10.1002/hep.27950
[2] P. Barreiro, P. Labarga, J. V. Fernandez-Montero, "Rate and indicators of serum HCV-RNA> 6 million IU/mL in patients with ceaseless hepatitis C," Diary of Clinical Virology, 1,71,pp.63-66, 2015.
https://doi.org/10.1016/j.jcv.2015.08.001
[3] M. Hickman, D. D. Angelis, P. Vickerman, S. Hutchinson, N. Martin, "HCV treatment as counteractive action in individuals who infuse drugs- testing the confirmation," Current sentiment 149 in irresistible infections, 28(6), pp.576, 2015.
https://doi.org/10.1097/QCO.0000000000000216
[4] M. Viganò, C.F Perno, A. Craxì, et al, "Treatment of Hepatitis C infection contamination in Italy: An agreement report from a specialist board," Digestive and Liver Disease, 49(7), pp.731-41, 2017.
https://doi.org/10.1016/j.dld.2017.03.027
[5] M. Cheung, D. Mutimer, K. Agarwal, A Brown, "Long haul genuine line up of patients with unending hepatitis C infection and decompensated cirrhosis after direct acting antivirals- what is the clinical advantage of antiviral treatment?,". Diary of Hepatology, 68, pp.109-110, 2018.
https://doi.org/10.1016/S0168-8278(18)30436-7
[6] D. L. Thomas, C. L. Thio, M. P. Martin, "Hereditary variety in IL28B and unconstrained freedom of hepatitis C infection", Nature, 461, pp.798- 801, 2009.
https://doi.org/10.1038/nature08463
[7] A. Al-Qahtani, M. Al-Anazi, A. A Abdom F. Sana, "Connection between's hereditary varieties and serum level of interleukin 28B with infection genotypes and illness movement in incessant hepatitis C infection disease," Journal of immunology look into, 2015.
https://doi.org/10.1155/2015/768470
[8] Y. Tanaka, N. Nishida, M. Sugiyama et al, "expansive relationship of IL28B with reaction to pegylated interferonalpha and ribavirin treatment for perpetual hepatitis C," Nature Genetics, 41,10, pp. 1105- 1109, 2009.
https://doi.org/10.1038/ng.449
[9] V. Suppiah, M. Moldovan, G. Ahlenstiel, "IL28B is related with reaction to endless hepatitis C interferon- and ribavirin treatment," Nature Genetics, vol. 41, no. 10, pp. 1100- 1104, 2009.
https://doi.org/10.1038/ng.447
[10] H. Abe, C. N. Hayes, H. Ochi et al, "IL28 variety influences articulation of interferon animated qualities and peg-interferon and ribavirin treatment," Journal of Hepatology, vol. 54, no. 6, pp. 1094- 1101, 2011.
https://doi.org/10.1016/j.jhep.2010.09.019
[11] N. Ank, H. West, C. Bartholdy, K. Eriksson, A. R. Thomsen, and S. R. Paludan, "Lambda interferon (IFN- ), a sort III IFN, is prompted by infections and IFNs and showcases powerful antiviral movement against select infection diseases in vivo," Journal of Virology, vol. 80, no. 9, pp. 4501- 4509, 2006.
https://doi.org/10.1128/JVI.80.9.4501-4509.2006
[12] J. Alarm, J. Pirhonen, I. Julkunen, and S. Matikainen, "IFN-' manages TLR-subordinate quality articulation of IFN-alpha, IFNbeta, IL-28, and IL-29," Journal of Immunology, vol. 174, no. 4, pp. 1932- 1937, 2005.
https://doi.org/10.4049/jimmunol.174.4.1932
[13] D. Ge D, J. Fellay, A. J. Thompson, J. S. Simon, K. V. Shianna, "Hereditary variety in IL28B predicts hepatitis C treatmentincited viral leeway. Nature," 461(7262), pp.399, 2009.
https://doi.org/10.1038/nature08309
[14] S. S. Ali, I. S Ali, A.H Amir, Z. Jadoon, S. Inayatullah, "Recurrence of hepatitis C disease in diabetic patients," J Ayub Med Coll Abbottabad 19(1) pp. 46-49, 2009.
[15] S. H. Mehta, F. H. Brancati, S. A Strathdee, et al, "Hepatitis C infection disease and episode write 2 diabetes," J Hepatol, 38 (1), pp. 244-252, 2003.
[16] F. Visnegarwala, L Chen, S. Raghavan, E. Tedaldi, "Predominance of diabetes mellitus and dyslipidemia among antiretroviral guileless patients co-tainted with hepatitis C infection (HCV) and HIV-1 contrasted with patients without cocontamination", J contaminate, 50(4),331-337, 2005.
https://doi.org/10.1016/j.jinf.2004.06.001
[17] M. H. Lee, H.I. Yang, C. J. Chen, "Long haul wellbeing results of perpetual hepatitis C patients: A survey of discoveries from REVEAL-HCV partner examine," Biomed,212(11), pp. 99- 107,2012.
https://doi.org/10.1016/j.biomed.2012.06.002
[18] B. A. Al-Haidary, S. Abdul-Kareem S, F.N. Azziz, R.J. AlAkaishi, A.Z. Al-Mousawy, "Viral load among the sera of Iraqi hepatitis C infection patients," Fac Med Baghdad, 49(4), pp.461-466,2007.
[19] M. Martinot-Peignoux, N. Boyer, D. Cazals-Hatem, et al, "Planned investigation on hostile to hepatitis C infection positive patients with diligently ordinary serum alanine transaminase with or without perceptible serum hepatitis C infection RNA," J Hepatol, 34, pp.1000-1005,2011.
https://doi.org/10.1053/jhep.2001.28458
[20] C Puoti, R. Castellacci, F. Montagnese, "Histological and virological highlights and follow-up of hepatitis C infection bearers with typical aminotransferase levels: the Italian imminent investigation of the asymptomatic C transporters (ISACC)," J Hepatol 2002;37:117-123.
https://doi.org/10.1016/S0168-8278(02)00101-0
[21] J.K. Mnuti, F.A AL-Abbudi, "Hepatitis C infection contamination appraisal among unending hemodialysis patients in al-Kadhmiya showing clinic," Iraqi postgraduate Med J, 10 (4) pp. 460-464, 2011.
[22] N. Tanaka, T. Nagaya T, M. Komatsu, "Insulin obstruction and hepatitis C infection: A case-control investigation of non-fat, non-alcoholic and non-steatotic hepatitis infection transporters with determinedly ordinary serum aminotransferase," Liver Int, 28, pp.1104-1111, 2008.
https://doi.org/10.1111/j.1478-3231.2008.01737.x
[23] R.H. Hussein, "Correlation in some biochemical and hematological tests between ceaseless hepatitis B and C," Ibn Al-Haitham J Pure Appl ScI, 24 (1), 155-162, 2011.
https://doi.org/10.1002/hep.27950
[2] P. Barreiro, P. Labarga, J. V. Fernandez-Montero, "Rate and indicators of serum HCV-RNA> 6 million IU/mL in patients with ceaseless hepatitis C," Diary of Clinical Virology, 1,71,pp.63-66, 2015.
https://doi.org/10.1016/j.jcv.2015.08.001
[3] M. Hickman, D. D. Angelis, P. Vickerman, S. Hutchinson, N. Martin, "HCV treatment as counteractive action in individuals who infuse drugs- testing the confirmation," Current sentiment 149 in irresistible infections, 28(6), pp.576, 2015.
https://doi.org/10.1097/QCO.0000000000000216
[4] M. Viganò, C.F Perno, A. Craxì, et al, "Treatment of Hepatitis C infection contamination in Italy: An agreement report from a specialist board," Digestive and Liver Disease, 49(7), pp.731-41, 2017.
https://doi.org/10.1016/j.dld.2017.03.027
[5] M. Cheung, D. Mutimer, K. Agarwal, A Brown, "Long haul genuine line up of patients with unending hepatitis C infection and decompensated cirrhosis after direct acting antivirals- what is the clinical advantage of antiviral treatment?,". Diary of Hepatology, 68, pp.109-110, 2018.
https://doi.org/10.1016/S0168-8278(18)30436-7
[6] D. L. Thomas, C. L. Thio, M. P. Martin, "Hereditary variety in IL28B and unconstrained freedom of hepatitis C infection", Nature, 461, pp.798- 801, 2009.
https://doi.org/10.1038/nature08463
[7] A. Al-Qahtani, M. Al-Anazi, A. A Abdom F. Sana, "Connection between's hereditary varieties and serum level of interleukin 28B with infection genotypes and illness movement in incessant hepatitis C infection disease," Journal of immunology look into, 2015.
https://doi.org/10.1155/2015/768470
[8] Y. Tanaka, N. Nishida, M. Sugiyama et al, "expansive relationship of IL28B with reaction to pegylated interferonalpha and ribavirin treatment for perpetual hepatitis C," Nature Genetics, 41,10, pp. 1105- 1109, 2009.
https://doi.org/10.1038/ng.449
[9] V. Suppiah, M. Moldovan, G. Ahlenstiel, "IL28B is related with reaction to endless hepatitis C interferon- and ribavirin treatment," Nature Genetics, vol. 41, no. 10, pp. 1100- 1104, 2009.
https://doi.org/10.1038/ng.447
[10] H. Abe, C. N. Hayes, H. Ochi et al, "IL28 variety influences articulation of interferon animated qualities and peg-interferon and ribavirin treatment," Journal of Hepatology, vol. 54, no. 6, pp. 1094- 1101, 2011.
https://doi.org/10.1016/j.jhep.2010.09.019
[11] N. Ank, H. West, C. Bartholdy, K. Eriksson, A. R. Thomsen, and S. R. Paludan, "Lambda interferon (IFN- ), a sort III IFN, is prompted by infections and IFNs and showcases powerful antiviral movement against select infection diseases in vivo," Journal of Virology, vol. 80, no. 9, pp. 4501- 4509, 2006.
https://doi.org/10.1128/JVI.80.9.4501-4509.2006
[12] J. Alarm, J. Pirhonen, I. Julkunen, and S. Matikainen, "IFN-' manages TLR-subordinate quality articulation of IFN-alpha, IFNbeta, IL-28, and IL-29," Journal of Immunology, vol. 174, no. 4, pp. 1932- 1937, 2005.
https://doi.org/10.4049/jimmunol.174.4.1932
[13] D. Ge D, J. Fellay, A. J. Thompson, J. S. Simon, K. V. Shianna, "Hereditary variety in IL28B predicts hepatitis C treatmentincited viral leeway. Nature," 461(7262), pp.399, 2009.
https://doi.org/10.1038/nature08309
[14] S. S. Ali, I. S Ali, A.H Amir, Z. Jadoon, S. Inayatullah, "Recurrence of hepatitis C disease in diabetic patients," J Ayub Med Coll Abbottabad 19(1) pp. 46-49, 2009.
[15] S. H. Mehta, F. H. Brancati, S. A Strathdee, et al, "Hepatitis C infection disease and episode write 2 diabetes," J Hepatol, 38 (1), pp. 244-252, 2003.
[16] F. Visnegarwala, L Chen, S. Raghavan, E. Tedaldi, "Predominance of diabetes mellitus and dyslipidemia among antiretroviral guileless patients co-tainted with hepatitis C infection (HCV) and HIV-1 contrasted with patients without cocontamination", J contaminate, 50(4),331-337, 2005.
https://doi.org/10.1016/j.jinf.2004.06.001
[17] M. H. Lee, H.I. Yang, C. J. Chen, "Long haul wellbeing results of perpetual hepatitis C patients: A survey of discoveries from REVEAL-HCV partner examine," Biomed,212(11), pp. 99- 107,2012.
https://doi.org/10.1016/j.biomed.2012.06.002
[18] B. A. Al-Haidary, S. Abdul-Kareem S, F.N. Azziz, R.J. AlAkaishi, A.Z. Al-Mousawy, "Viral load among the sera of Iraqi hepatitis C infection patients," Fac Med Baghdad, 49(4), pp.461-466,2007.
[19] M. Martinot-Peignoux, N. Boyer, D. Cazals-Hatem, et al, "Planned investigation on hostile to hepatitis C infection positive patients with diligently ordinary serum alanine transaminase with or without perceptible serum hepatitis C infection RNA," J Hepatol, 34, pp.1000-1005,2011.
https://doi.org/10.1053/jhep.2001.28458
[20] C Puoti, R. Castellacci, F. Montagnese, "Histological and virological highlights and follow-up of hepatitis C infection bearers with typical aminotransferase levels: the Italian imminent investigation of the asymptomatic C transporters (ISACC)," J Hepatol 2002;37:117-123.
https://doi.org/10.1016/S0168-8278(02)00101-0
[21] J.K. Mnuti, F.A AL-Abbudi, "Hepatitis C infection contamination appraisal among unending hemodialysis patients in al-Kadhmiya showing clinic," Iraqi postgraduate Med J, 10 (4) pp. 460-464, 2011.
[22] N. Tanaka, T. Nagaya T, M. Komatsu, "Insulin obstruction and hepatitis C infection: A case-control investigation of non-fat, non-alcoholic and non-steatotic hepatitis infection transporters with determinedly ordinary serum aminotransferase," Liver Int, 28, pp.1104-1111, 2008.
https://doi.org/10.1111/j.1478-3231.2008.01737.x
[23] R.H. Hussein, "Correlation in some biochemical and hematological tests between ceaseless hepatitis B and C," Ibn Al-Haitham J Pure Appl ScI, 24 (1), 155-162, 2011.
Downloads
How to Cite
[1]
M. Abdullah Alazzawy, “Role of Interleukin-28B in clearance of HCV in acute and chronic hepatitis patients in Kirkuk city”, KJAR, vol. 3, no. 2, pp. 146–149, Jul. 2018, doi: 10.24017/science.2018.2.24.
Article Metrics
Published
23-07-2018
Issue
Section
Pure and Applied Science
